The Molecular Targets Center of Biomedical Research Excellence (MT COBRE) at the University of Louisville and the James Graham Brown Cancer Center has successful supported the early career of fourteen junior faculty members during its Phase I and il funding periods. The current application reflects the maturation of the Molecular Targets Program and its faculty. The overall goal of the Phase III application of the Molecular Targets COBRE will be to ensure that the novel targets and compounds which have been identified by MT COBRE faculty are translated to pivotal human clinical trials. Several strengths have enhanced the success of this program including: 1) Stability of program leadership;2) Successful retention of all fourteen faculty members;3) Institutional support for the program totaling over $30M;and 4) Creation of a University of Louisville-owned company dedicated to translating important discoveries of MT COBRE investigators. The ability of MT COBRE faculty to test their novel compounds in humans will distinguish this program from similar programs at other institutions.'To this end, the MT COBRE has supported the development of a unique translational research infrastructure which has enabled the characterization of more than 30 novel targets. The Phase III application will support four closely integrated core facilities which will support this goal;1) Microarray Core;2) Molecular Modeling Core;3) NMR/Metabolomic Core and 4) Animal Model Core. Additionally, the James Graham Brown Cancer Center has created complementary research cores which will be available to MT Program members during the Phase III component of the program including the Biostatistics Core, Clinical Trials Office, Biophysical Cancer Core, Cell Sorting and Flow Cytometry Core. The MT COBRE administration will continue to provide intensive support for development of the fourteen faculty members, many of whom have assumed leadership roles within the Cancer Center and University. The robust translational research infrastructure at the James Graham Brown Cancer Center and University of Louisville will ensure the success and sustainability of this unique program.

Public Health Relevance

Cancer metabolism and cancer drug development are currently very important areas of research. The MT COBRE program has trained leaders in this area;the funding of Phase III will ensure the continued success and growth of the core facilities and this program.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30GM106396-02
Application #
8687689
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Canto, Maria Teresa
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40202
Shah, P P; Lockwood, W W; Saurabh, K et al. (2015) Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells. Oncogene 34:1709-17
Zhao, Guoping; Zhu, Yanglong; Eno, Colins O et al. (2014) Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol 34:1198-207
Gray, Robert D; Trent, John O; Chaires, Jonathan B (2014) Folding and unfolding pathways of the human telomeric G-quadruplex. J Mol Biol 426:1629-50
Wilburn, Damien B; Bowen, Kathleen E; Doty, Kari A et al. (2014) Structural insights into the evolution of a sexy protein: novel topology and restricted backbone flexibility in a hypervariable pheromone from the red-legged salamander, Plethodon shermani. PLoS One 9:e96975